STOCK TITAN
  1. Home
  2. News
  3. BFRI

Biofrontera Inc - BFRI STOCK NEWS

IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)
fda approval
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
conferences
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer Accounts
management
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)
clinical trial
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business Update
earnings
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz(R)-PDT for the Treatment of Basal Cell Carcinoma
clinical trial
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023
conferences earnings
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%
IMPACT
SENTIMENT
BFRI : Nasdaq
Biofrontera Inc. Appoints Dr. Heikki Lanckriet to its Board of Directors
management
Stock BFRI logo
Biofrontera Inc
Nasdaq:BFRI

BFRI Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing

About BFRI

biofrontera pharma gmbh is a pharmaceuticals company based out of 104 waldhofer straße, heidelberg, bw, germany.